{
    "symbol": "ADMP",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-14 22:03:03",
    "content": " Despite still being negatively impacted by the SYMJEPI recall, total net revenue for the quarter ending September 30, 2022 was $1.5 million compared to $760,000 for the same quarter in 2021. I also attempted to establish the expectation that the heavy lift in the first few quarters of any drug launch is laying the necessary foundation through a tedious process of adding the drug to the formularies of both insurers and prescription benefit managers contracting with -- directly with customers, et cetera."
}